Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Arthritis Care & Research|October 17, 2015
Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical TrialPaul Emery, Roy M Fleischmann, Ingrid Strusberg, et al.
Advances in Therapy|August 10, 2022
The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 TrialJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
Molecular Breeding : New Strategies in Plant Improvement|January 19, 2026
Evaluation of yield and eating quality of representative indica and japonica rice varieties in response to nitrogen levelsYuankang Cai, Shijie Shi, Jun Lu, et al.
Gastroenterology|March 20, 2025
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI StudyAilsa Hart, Remo Panaccione, Flavio Steinwurz, et al.
Gastroenterology|September 2, 2023
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction StudyLaurent Peyrin-Biroulet, Jessica R Allegretti, David T Rubin, et al.
The Lancet. Gastroenterology & Hepatology|December 17, 2023
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialSilvio Danese, Remo Panaccione, Brian G Feagan, et al.
Gastroenterology|February 8, 2022
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 StudyWilliam J Sandborn, Geert R D'Haens, Walter Reinisch, et al.
Lancet (London, England)|July 20, 2025
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trialsRemo Panaccione, Brian G Feagan, Anita Afzali, et al.
Pageof 9